Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Pfizer Inc. is conducting a Phase 3 study titled ‘A Phase 3 Multi-Center, Long-Term Extension Study Investigating the Efficacy and Safety of Abrocitinib, With or Without Topical Medications, Administered to Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis.’ The study aims to evaluate the efficacy and safety of Abrocitinib, an oral medication, in treating moderate to severe atopic dermatitis in patients aged 12 and older. This study is significant as it explores long-term treatment options for a chronic skin condition that affects a significant portion of the population.
The intervention being tested is Abrocitinib, available in two dosage strengths: 100 mg and 200 mg, taken orally once daily. The purpose of this drug is to manage symptoms of atopic dermatitis, potentially providing a new treatment avenue for patients.
The study design is interventional, with participants randomly assigned to different treatment groups in a parallel model. The study employs quadruple masking, meaning the participant, care provider, investigator, and outcomes assessor are all blinded to the treatment allocation. The primary purpose of the study is treatment-focused.
The study began on March 8, 2018, and is currently active but not recruiting new participants. The primary completion date is not specified, but the last update was submitted on July 28, 2025. These dates are crucial as they indicate the study’s progress and timeline for potential results.
The market implications of this study are significant for Pfizer, as positive outcomes could enhance their market position in the dermatology sector, potentially boosting stock performance. Investors should also consider the competitive landscape, as other pharmaceutical companies are developing treatments for atopic dermatitis.
The study is ongoing, with further details available on the ClinicalTrials portal.